Across TCGA pan-cancer cohorts, HSP90B3P Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSP90B3P data layer compared with 22 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher HSP90B3P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSP90B3P expression acts as an unfavorable survival marker.
OV, LAML, and LUSC are the cancer types where HSP90B3P Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.